BM
ACAD icon

Bridger Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bridger Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-117,341
Closed -$3.67M – 32
2023
Q4 		$3.67M Buy
+117,341
New +$2.8M 1.41% 18

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bridger Management's ACAD Position: Q1 2024 in Review

Bridger Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 117,341 shares — an estimated $3.67M sold.

Bridger Management first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $3.67M in Q4 2023. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Bridger Management reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Bridger Management sold 117,341 Acadia Pharmaceuticals shares in Q1 2024, an estimated $3.67M.
  • Bridger Management first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Bridger Management's Acadia Pharmaceuticals position peaked at $3.67M in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Bridger Management's 13F filing for Q1 2024, filed 15 May 2024.